These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 34010403)

  • 1. Tocilizumab in the treatment of COVID-19-a meta-analysis.
    Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
    QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.
    Piscoya A; Parra Del Riego A; Cerna-Viacava R; Rocco J; Roman YM; Escobedo AA; Pasupuleti V; White CM; Hernandez AV
    PLoS One; 2022; 17(6):e0269368. PubMed ID: 35657993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
    Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
    J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
    Zhang J; Chen C; Yang Y; Yang J
    Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
    Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
    Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
    Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
    Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
    Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
    Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
    Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
    Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
    Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
    Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
    Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
    Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
    Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
    Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
    Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.